Riskpilot← Back to searchSign inGet full accessHepGene Medical AB
ABActiveOrg 5590556592Varpetvägen 9Medical specialists activities · NACE 8622Est. 20161-4 employees
Revenue 2025
SEK 1M
+8% vs 2024
EBITDA margin
57.2%
-7% vs 2024
Equity ratio
97.3%
Financial strength
Net profit 2025
SEK 426K
-4% vs 2024
| Revenue | SEK 1M | +8% |
| EBITDA | SEK 597K | -7% |
| Net profit | SEK 426K | -4% |
| Total assets | SEK 2M | +7% |
| Equity | SEK 1,9M | +13% |
| Employees | — | — |
Legal name
HepGene Medical AB
Org number
5590556592
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
17 mars 2016
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-02-28
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
- erbjuder tjänster som konsultläkare inom internmedicin, allmänmedicin, gastroenterologi, hepatologi, endoskopisk verksamhet och medicinsk forskning. - ansöker om patent inom medicinsk forskning. - äga och förvalta aktier samt därmed förenlig verksamhet.
Address
Varpetvägen 9
Email
hepgenemedical@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 001 | 1 531 | 1 223 | 968 | 1 043 |
| Staff expenses | — | — | −98 | −64 | −249 |
| EBITDA | 346 | 1 124 | 818 | 644 | 597 |
| Depreciation & amort. | −48 | −48 | −89 | −145 | −147 |
| EBIT | 298 | 1 076 | 729 | 499 | 450 |
| Net financials | — | 21 | 39 | 60 | 90 |
| Profit before tax | 297 | 1 107 | 801 | 559 | 539 |
| Tax | −65 | −232 | −167 | −114 | −113 |
| Net profit | 232 | 875 | 634 | 445 | 426 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 208 | 1 240 | 1 665 | 1 829 | 1 956 |
| Equity | 497 | 982 | 1 426 | 1 682 | 1 904 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 678 | 225 | 239 | 147 | 52 |
| Total debt | 678 | 225 | 239 | 147 | 52 |
EBITDA margin
57.2%
This company
15.8%
Market median
+262% vs market
20212025
Equity ratio
97.3%
This company
38.2%
Market median
+155% vs market
20212025
Return on equity
22.4%
This company
18.4%
Market median
+22% vs market
20212025
Net profit margin
40.8%
This company
8.1%
Market median
+404% vs market
20212025
Asset turnover
0.53×
This company
1.12×
Market median
-53% vs market
20212025
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-03-01 – 2025-02-28
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-03-01 – 2024-02-29
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-03-01 – 2023-02-28
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-03-01 – 2022-02-28
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-03-01 – 2021-02-28
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JM Chief Executive Officer | Chief Executive Officer | 2022 |
RM Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of HepGene Medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Martin Waern | Chief Executive Officer | 0 companies |
| Rebecca Marianne Yhland Waern | Deputy Chief Executive Officer | 0 companies |